Please login to the form below

Not currently logged in
Email:
Password:

acalabrutinib

This page shows the latest acalabrutinib news and features for those working in and with pharma, biotech and healthcare.

Merck buys ArQule for $2.7bn in another cancer bolt-on deal

Merck buys ArQule for $2.7bn in another cancer bolt-on deal

ARQ 531 is in the same general class as Johnson &Johnson’s Imbruvica (ibrutinib) and AstraZeneca’s Calquence (acalabrutinib), but is a reversible, non-covalent inhibitor that zeroes in on a

Latest news

More from news
Approximately 1 fully matching, plus 24 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hanson Zandi

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Latest intelligence

Happy Chinese New Year 2020 - The Year of The Rat
A fond farewell to The Year of the Pig...
White Paper for download - Explaining the price of your product
In this white paper, he breaks down the pricing options available to you, shares stories from his extensive experiences, and talks you through how to better define your pricing, step-by-step....
OPEN Health expands offering with the launch of a new Learning & Development specialist team
Enhanced expertise to deliver impactful internal training programmes for healthcare clients...

Infographics